Desley van Zoggel

Improved outcomes for responders to induction chemotherapy 41 CHAPTER 3 Table 2. Characteristics recurrent tumour and treatment Total N = 132 Number local recurrence First 116 (88) Second/Third 16 (12) Multifocality Yes 27 (20) No 105 (80) Lateral involvement Yes 69 (52) No 63 (48) History of metastases Yes 29 (22) No 103 (78) Synchronous metastases Yes 35 (27) No 97 (73) Type metastasisa Liver 13 Lung 10 Inguinal lymph nodes 2 Peritoneal 10 Other 3 Neoadjuvant radiotherapy (Chemo)radiotherapy 24 (18) (Chemo)reirradiation 108 (82) Surgical procedure Low anterior resection 14 (11) Abdominoperineal resection 16 (12) Multivisceral resection 50 (38) Total pelvic exenteration 25 (19) Resection n.o.s. 27 (20) HIPEC Yes 8 (4) No 124 (96) IOERT Yes 111 (84) No 21 (16) Time to recurrence (months)b Median [IQR] 32 [21–51] Time radiotherapy-surgery (weeks) Median [IQR] 12 [10–14] Bloodloss (mL) Median [IQR] 2350 [1225–3500] Values in parentheses are percentages unless indicated otherwise. a Some patients had metastases in more than one organ b Time between primary surgery and current recurrence LAR lowanterior resection, APR abdominoperineal resection, Resectionn.o.s. resectionnot otherwise specified, resection recurrence without bowel resection, HIPEC hyperthermic intraperitoneal chemotherapy, IOERT intraoperative electron beam radiotherapy

RkJQdWJsaXNoZXIy MTk4NDMw